- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2003.
- Why 3/10
- No hard, dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for ALDURAZYME in the next 12 months. It is an already-approved, commercialized drug. Per the rubric, an approved drug with no pending regulatory decision scores 3-5. At roughly 6.5% of BioMarin's total revenue, it is a modest contributor to a diversified portfolio, supporting the lower end of that range.
ALDURAZYME has no upcoming PDUFA dates, pivotal readouts, or regulatory decisions. The next meaningful data point for this drug is routine quarterly revenue disclosures within BioMarin's earnings reports. For BioMarin stock, the far larger value drivers are VOXZOGO (achondroplasia) and the recently acquired Amicus Therapeutics portfolio. ALDURAZYME is not a catalyst for BMRN shares.
Price Chart
Executive Summary
ALDURAZYME (laronidase) is a mature, FDA-approved enzyme replacement therapy for the rare genetic disorder mucopolysaccharidosis I (MPS I). Approved in 2003, it was BioMarin's first drug and is manufactured by BioMarin but marketed globally through a 50/50 joint venture with Sanofi/Genzyme. With 2025 revenue of $208.5 million (roughly 6.5% of BioMarin's $3.2 billion total revenue), it is a steady but modest contributor to a much larger and more diversified portfolio now led by VOXZOGO. There are no upcoming binary catalysts for this drug, and no approved U.S. biosimilars, though a biosimilar candidate from Iran's CinnaGen has been studied. The drug faces long-term pipeline pressure from gene therapies in development.
How It Works
ALDURAZYME is an enzyme replacement therapy. Patients with MPS I are born with a genetic deficiency of the enzyme alpha-L-iduronidase, which normally breaks down certain sugar molecules (glycosaminoglycans) in cells. Without it, these sugars accumulate and cause organ damage. ALDURAZYME provides a synthetic version of the missing enzyme via weekly intravenous infusion, helping clear the accumulated sugars.
Trial Status
ALDURAZYME was approved by the FDA on April 30, 2003, based on a pivotal placebo-controlled Phase 3 study in 45 MPS I patients that showed improvements in pulmonary function and walking distance. It has been commercially available for over 23 years. A biosimilar version (CinnaGen) has completed a Phase 3 crossover study versus Aldurazyme, but no U.S. biosimilar has been approved.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for this specific drug. ALDURAZYME is a mature marketed product with no pending regulatory decisions or pivotal trial readouts.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report